Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $6.7 million.

  • Zevra Therapeutics' Net Cash Flow fell 5636.54% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$621000.0, marking a year-over-year decrease of 10583.76%. This contributed to the annual value of -$9.7 million for FY2024, which is 5673.39% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Net Cash Flow of $6.7 million as of Q3 2025, which was down 5636.54% from $9.7 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Net Cash Flow peaked at $71.7 million during Q1 2021, and registered a low of -$25.3 million during Q1 2023.
  • Over the past 5 years, Zevra Therapeutics' median Net Cash Flow value was -$792000.0 (recorded in 2021), while the average stood at $2.6 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Net Cash Flow surged by 717838.1% in 2021, and later crashed by 357750.44% in 2024.
  • Zevra Therapeutics' Net Cash Flow (Quarter) stood at -$19.2 million in 2021, then soared by 74.68% to -$4.8 million in 2022, then soared by 88.27% to -$569000.0 in 2023, then crashed by 3577.5% to -$20.9 million in 2024, then surged by 131.84% to $6.7 million in 2025.
  • Its Net Cash Flow was $6.7 million in Q3 2025, compared to $9.7 million in Q2 2025 and $3.9 million in Q1 2025.